Abstract
The most common cause of apparent ineffectiveness or resistance to treatment with oral levothyroxine (LT4) is the result of noncompliance, known as pseudomalabsorption. However, an abnormality in the bioavailability of LT4 should also be considered in patients requiring large doses of LT4 to achieve euthyroidism. The incidence of lactose intolerance in Caucasian adult patients is 7%–20%, but the association with resistance to treatment with oral LT4 is unusual. We report a 55-year-old woman in whom treatment LT4 for hypothyroidism was found related to a previously undiagnosed oligo-symptomatic lactose intolerance, an unusual association. Although rare, intolerance to lactose should be considered in the differential diagnosis of gastrointestinal diseases that can cause malabsorption of LT4. The possibility of correcting this disorder with simple dietary measures justifies its consideration.
Get full access to this article
View all access options for this article.
